Without an adcomm, FDA signs off on second Covid-19 booster for those over 50
The FDA on Tuesday authorized a second booster shot of both the Pfizer-BioNTech and Moderna Covid-19 vaccines for all adults over the age of 50 at least 4 months after receipt of a first booster dose.
Although the agency relied on real world evidence from Israel to make its decision, and it did not seek the opinion of an advisory committee of outside experts before the authorization, Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, didn’t think it was a controversial decision.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.